Wnt pathway antagonists

Compounds of formula I

• wherein, as valence and stability permit:
• any carbon-bound hydrogen atom may be substituted with a fluorine atom;
• X1 is CR2 or N;
• X2 is CR3 or N;
• -Y-Q is
• Q is C1-C6 linear branched or cylic alkyl, alkylcarbonyl, oxalkyl, dioxalkyl, alkylaminocarbonyl, oxalkylamminocarbonyl group wherein any methylene group may be substituted with an oxo group;
• a C5-C10 aryl or heteroaryl group optionally substituted with 1, 2 or 3 groups selected from the list of C1-C6 linear branched or cyclic alkyl, oxalkyl, alkylamino, alkylaminocarbonyl, oxalkylamino, oxalkyloxy, azalkyloxy, halogen, cyano, or a C5-C6 aryl or heteroaryl group optionally substituted with halogen, C1-C3 alkyl, C1-C3 oxalkyl;
• R1 is H;
• F;
• Cl;
• Br;
• OH;
• CN;
• linear branched or cyclic C1-C6 alkyl, alkenyl, alkynyl, oxalkyl, oxalkenyl, oxalkynil, azalkenyl, azalkynyl, alkyloxy, alkenyloxy, oxalkyloxy, dioxalkyloxy, oxazalkyloxy, azalkyloxy, dialkylamino, oxalkylamino, azalkylamino, group optionally substituted with one or more F or CN;
• C5-C6 aryl- or heteroarylmethylammino or C5-C6 aryl- or heterorylmethyloxy group where the aryl or heteroaryl moiety may optionally be substituted with one or more C1-C3 alkyl, C1-C3 alkoxy, halogen or CN groups;
• R2 is H or Cl;
• R3 is H, Cl or F;
• R4 is H or Cl;
• R5 is a C1-C3 linear, branched or cylic alkyl group;
• Rx is H;
• a linear, branched or cyclic C1-C3 alkyl group;
• n may be nil, 1, 2 or 3;
• Ry is—independently from one another when n=2 or more—F;
• a linear, branched or cyclic C1-C3 alkyl group;
• or Ry, together with the carbon atom to which it is attached, forms an oxo group.
• X3 is either N, O or S;
• tautomers, optical isomers and pharmaceutically acceptable salts thereof;
• with the exception of